MetaCap

GT Biopharma (GTBP) vs Exicure (XCUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GT Biopharma is the larger company by market cap ($6.3 million vs $5.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GTBP-52.26%XCUR-11.75%
+22%-17%-56%
Oct 7, 20261 yearNov 20, 2026
GTBP-55.69%XCUR-14.28%
+10%-25%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GTBP versus XCUR key metrics
MetricGTBPXCUR
Share price$2.96$0.9001
Market cap$6.33M$5.89M
1-day change-6.92%-12.82%
YTD return+277.07%—
1-year return+303.27%—
5-year return-97.77%—
EPS (TTM)$-128.61$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-28.35M$-4.95M
52-week high$23.60$9.48
52-week low$2.87$0.777
Distance from 52-week high-87.46%-90.51%
Analyst consensusnone—
Avg. price target upside+2433.78%—
Average volume78.16K53.56K
Shares outstanding2.14M6.55M
Employees11
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

About Exicure

XCUR stock →

Exicure, Inc. does not have significant operations.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

GTBP vs XCUR FAQ

Which is bigger, GT Biopharma or Exicure?

GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $5.89M for Exicure (XCUR).

Are GT Biopharma and Exicure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons